Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records.

Meyer JM, Ng-Mak DS, Chuang CC, Rajagopalan K, Loebel A.

Ann Gen Psychiatry. 2017 Oct 17;16:36. doi: 10.1186/s12991-017-0159-x. eCollection 2017.

2.

Diagnosis and body mass index effects on hippocampal volumes and neurochemistry in bipolar disorder.

Bond DJ, Silveira LE, MacMillan EL, Torres IJ, Lang DJ, Su W, Honer WG, Lam RW, Yatham LN.

Transl Psychiatry. 2017 Mar 28;7(3):e1071. doi: 10.1038/tp.2017.42.

3.

Metabolic syndrome and adverse clinical outcomes in patients with bipolar disorder.

Bai YM, Li CT, Tsai SJ, Tu PC, Chen MH, Su TP.

BMC Psychiatry. 2016 Dec 15;16(1):448.

4.

Zonisamide for Bipolar Depression: A Randomized, Double Blind, Placebo-Controlled, Adjunctive Trial.

Dauphinais D, Knable M, Rosenthal J, Polanski M, Rosenthal N.

Psychopharmacol Bull. 2011 May 15;44(2):73-84.

5.

Lifestyle interventions targeting dietary habits and exercise in bipolar disorder: A systematic review.

Bauer IE, Gálvez JF, Hamilton JE, Balanzá-Martínez V, Zunta-Soares GB, Soares JC, Meyer TD.

J Psychiatr Res. 2016 Mar;74:1-7. doi: 10.1016/j.jpsychires.2015.12.006. Epub 2015 Dec 12. Review.

6.

Modeling mania in preclinical settings: A comprehensive review.

Sharma AN, Fries GR, Galvez JF, Valvassori SS, Soares JC, Carvalho AF, Quevedo J.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Apr 3;66:22-34. doi: 10.1016/j.pnpbp.2015.11.001. Epub 2015 Nov 4. Review.

7.

Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial.

Yatham LN, Beaulieu S, Schaffer A, Kauer-Sant'Anna M, Kapczinski F, Lafer B, Sharma V, Parikh SV, Daigneault A, Qian H, Bond DJ, Silverstone PH, Walji N, Milev R, Baruch P, da Cunha A, Quevedo J, Dias R, Kunz M, Young LT, Lam RW, Wong H.

Mol Psychiatry. 2016 Aug;21(8):1050-6. doi: 10.1038/mp.2015.158. Epub 2015 Oct 13.

8.

Bipolar disorder in women.

Parial S.

Indian J Psychiatry. 2015 Jul;57(Suppl 2):S252-63. doi: 10.4103/0019-5545.161488. Review.

9.

Cerebral White Matter Lesions and Affective Episodes Correlate in Male Individuals with Bipolar Disorder.

Birner A, Seiler S, Lackner N, Bengesser SA, Queissner R, Fellendorf FT, Platzer M, Ropele S, Enzinger C, Schwingenschuh P, Mangge H, Pirpamer L, Deutschmann H, McIntyre RS, Kapfhammer HP, Reininghaus B, Reininghaus EZ.

PLoS One. 2015 Aug 7;10(8):e0135313. doi: 10.1371/journal.pone.0135313. eCollection 2015.

10.

Obesity, but not metabolic syndrome, negatively affects outcome in bipolar disorder.

McElroy SL, Kemp DE, Friedman ES, Reilly-Harrington NA, Sylvia LG, Calabrese JR, Rabideau DJ, Ketter TA, Thase ME, Singh V, Tohen M, Bowden CL, Bernstein EE, Brody BD, Deckersbach T, Kocsis JH, Kinrys G, Bobo WV, Kamali M, McInnis MG, Leon AC, Faraone S, Nierenberg AA, Shelton RC.

Acta Psychiatr Scand. 2015 Jun 26. doi: 10.1111/acps.12460. [Epub ahead of print]

11.

Illness progression as a function of independent and accumulating poor prognosis factors in outpatients with bipolar disorder in the United States.

Post RM, Altshuler LL, Leverich GS, Nolen WA, Kupka R, Grunze H, Frye MA, Suppes T, McElroy SL, Keck PE Jr, Rowe M.

Prim Care Companion CNS Disord. 2014 Dec 18;16(6). doi: 10.4088/PCC.14m01677. eCollection 2014.

12.

Neurocognitive functioning in overweight and obese patients with bipolar disorder: data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).

Silveira LE, Kozicky JM, Muralidharan K, Bücker J, Torres IJ, Bond DJ, Kapczinski F, Kauer-Sant'Anna M, Lam RW, Yatham LN.

Can J Psychiatry. 2014 Dec;59(12):639-48.

13.

An Integrated Risk Reduction Intervention can reduce body mass index in individuals being treated for bipolar I disorder: results from a randomized trial.

Frank E, Wallace ML, Hall M, Hasler B, Levenson JC, Janney CA, Soreca I, Fleming MC, Buttenfield J, Ritchey FC, Kupfer DJ.

Bipolar Disord. 2015 Jun;17(4):424-37. doi: 10.1111/bdi.12283. Epub 2014 Dec 12.

14.

Co-morbidity in Bipolar Disorder: A Retrospective Study.

Munoli RN, Praharaj SK, Sharma PS.

Indian J Psychol Med. 2014 Jul;36(3):270-5. doi: 10.4103/0253-7176.135377.

15.

Cardiometabolic Health in Bipolar Disorder.

Kemp DE, Fan J.

Psychiatr Ann. 2012 May 1;42(5):179-183. No abstract available.

16.

The health benefits and challenges of exercise training in persons living with schizophrenia: a pilot study.

Bredin SS, Warburton DE, Lang DJ.

Brain Sci. 2013 May 24;3(2):821-48. doi: 10.3390/brainsci3020821.

17.

Nutrition, Exercise, and Wellness Treatment in bipolar disorder: proof of concept for a consolidated intervention.

Sylvia LG, Salcedo S, Bernstein EE, Baek JH, Nierenberg AA, Deckersbach T.

Int J Bipolar Disord. 2013 Oct 1;1(1):24. doi: 10.1186/2194-7511-1-24.

18.

Prevalence of cardiovascular risk factors among racial and ethnic minorities with schizophrenia spectrum and bipolar disorders: a critical literature review.

Carliner H, Collins PY, Cabassa LJ, McNallen A, Joestl SS, Lewis-Fernández R.

Compr Psychiatry. 2014 Feb;55(2):233-47. doi: 10.1016/j.comppsych.2013.09.009. Epub 2013 Oct 22.

19.

Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study.

McElroy SL, Guerdjikova AI, Kim DD, Burns C, Harris-Collazo R, Landbloom R, Dunayevich E.

Prim Care Companion CNS Disord. 2013;15(3). pii: PCC.12m01494. doi: 10.4088/PCC.12m01494. Epub 2013 Jun 20.

20.

Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.

Kemp DE, Correll CU, Tohen M, Delbello MP, Ganocy SJ, Findling RL, Chang K.

J Child Adolesc Psychopharmacol. 2013 Oct;23(8):522-30. doi: 10.1089/cap.2012.0099. Epub 2013 Oct 10.

Supplemental Content

Support Center